Improvement of albuminuria after renal denervation

International Journal of Cardiology

Volumn 173, Issue 2, 2014, Pages 311-315

  Ott, Christian ^a   Mahfoud, Felix ^b   Schmid, Axel ^a   Ditting, Tilmann ^a   Veelken, Roland ^a   Ewen, Sebastian ^b   Ukena, Christian ^b   Uder, Michael ^a   Böhm, Michael ^b   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Albuminuria; Blood pressure; Renal denervation; Renal organ damage; Treatment resistant hypertension; Urinary albumin to creatinine ratio

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALBUMIN; ALDOSTERONE ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIURETIC AGENT; HEPARIN; VASODILATOR AGENT;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATHETER; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HEART RATE; HUMAN; KIDNEY DENERVATION; KIDNEY FUNCTION; KIDNEY INJURY; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PREVALENCE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RESISTANT HYPERTENSION; RISK FACTOR; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; AGED; BLOOD PRESSURE; CATHETER ABLATION; COMPLICATION; HYPERTENSION; INNERVATION; KIDNEY; KIDNEY FUNCTION TEST; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; PROGNOSIS; SYMPATHECTOMY; URINE;

AGED; ALBUMINURIA; BLOOD PRESSURE; CATHETER ABLATION; CREATININE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; SYMPATHECTOMY;

EID: 84898619128     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.03.017     Document Type: Article

References (51)

1. L.M. Ruilope, and G.L. Bakris Renal function and target organ damage in hypertension Eur Heart J 32 2011 1599 1604
2. M. van der Velde, K. Matsushita, and J. Coresh et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts Kidney Int 79 2011 1341 1352
3. V. Perkovic, C. Verdon, and T. Ninomiya et al. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis PLoS Med 5 2008 e207
4. H.L. Hillege, V. Fidler, and G.F. Diercks et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population Circulation 106 2002 1777 1782
5. T. Ninomiya, V. Perkovic, and B.E. de Galan et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes J Am Soc Nephrol 20 2009 1813 1821
6. K. Matsushita, M. van der Velde, and B.C. Astor et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Lancet 375 2010 2073 2081
7. R.E. Katholi Renal nerves in the pathogenesis of hypertension in experimental animals and humans Am J Physiol 245 1983 F1 F14
8. V.M. Campese, and E. Kogosov Renal afferent denervation prevents hypertension in rats with chronic renal failure Hypertension 25 1995 878 882
9. G.F. DiBona, and U.C. Kopp Neural control of renal function Physiol Rev 77 1997 75 197
10. M.P. Schlaich, F. Socratous, and S. Hennebry et al. Sympathetic activation in chronic renal failure J Am Soc Nephrol 20 2009 933 939
11. M.D. Esler, H. Krum, P.A. Sobotka, M.P. Schlaich, R.E. Schmieder, and M. Bohm Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial Lancet 376 2010 1903 1909
12. V.M. Campese, E. Kogosov, and M. Koss Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat Am J Kidney Dis 26 1995 861 865
13. S. Ye, B. Ozgur, and V.M. Campese Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure Kidney Int 51 1997 722 727
14. F.J. Mena-Martin, J.C. Martin-Escudero, F. Simal-Blanco, J.L. Carretero-Ares, D. Arzua-Mouronte, and J.J. Castrodeza Sanz Influence of sympathetic activity on blood pressure and vascular damage evaluated by means of urinary albumin excretion J Clin Hypertens (Greenwich) 8 2006 619 624
15. K. Hoogenberg, W.J. Sluiter, and G. Navis et al. Exogenous norepinephrine induces an enhanced microproteinuric response in microalbuminuric insulin-dependent diabetes mellitus J Am Soc Nephrol 9 1998 643 654
16. H. Krum, M. Schlaich, and R. Whitbourn et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 2009 1275 1281
17. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months Hypertension 57 2011 911 917
18. M.D. Esler, H. Krum, M. Schlaich, R.E. Schmieder, M. Bohm, and P.A. Sobotka Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial Circulation 126 2012 2976 2982
19. F. Mahfoud, C. Ukena, and R.E. Schmieder et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension Circulation 128 2013 132 140
20. C. Ott, F. Mahfoud, and A. Schmid et al. Renal denervation in moderate treatment-resistant hypertension J Am Coll Cardiol 62 2013 1880 1886
21. F. Mahfoud, B. Cremers, and J. Janker et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension Hypertension 60 2012 419 424
22. C. Ott, R. Janka, and A. Schmid et al. Vascular and renal hemodynamic changes after renal denervation Clin J Am Soc Nephrol 8 2013 1195 1201
23. D. Hering, F. Mahfoud, and A.S. Walton et al. Renal denervation in moderate to severe CKD J Am Soc Nephrol 23 2012 1250 1257
24. M.G. Kiuchi, G.L. Maia, and M.A. de Queiroz Carreira et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension Eur Heart J 34 2013 2114 2121
25. A.V. Chobanian, G.L. Bakris, and H.R. Black et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
26. G. Mancia, R. Fagard, and K. Narkiewicz et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 34 2013 2159 2219
27. R.E. Schmieder, J. Redon, and G. Grassi et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension J Hypertens 30 2012 837 841
28. R.E. Schmieder, J. Redon, and G. Grassi et al. Updated ESH position paper on interventional therapy of resistant hypertension EuroIntervention 9 Suppl. R 2013 R58 R66
29. E. O'Brien, T. Pickering, and R. Asmar et al. Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults Blood Press Monit 7 2002 3 17
30. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Kidney Int Suppl 3 2013 1 150
31. A.S. Levey, L.A. Stevens, and C.H. Schmid et al. A new equation to estimate glomerular filtration rate Ann Intern Med 150 2009 604 612
32. R.T. Gansevoort, R. Correa-Rotter, and B.R. Hemmelgarn et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention Lancet 382 2013 339 352
33. B.M. Brenner, M.E. Cooper, and D. de Zeeuw et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
34. H.H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, and P. Arner The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
35. D. de Zeeuw, G. Remuzzi, and H.H. Parving et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL Kidney Int 65 2004 2309 2320
36. J. Schrader, S. Luders, and A. Kulschewski et al. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)* J Hypertens 24 2006 541 548
37. R.E. Schmieder, J.F. Mann, and H. Schumacher et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease J Am Soc Nephrol 22 2011 1353 1364
38. R. Veelken, E.M. Vogel, and K. Hilgers et al. Autonomic renal denervation ameliorates experimental glomerulonephritis J Am Soc Nephrol 19 2008 1371 1378
39. M.C. Brandt, F. Mahfoud, and S. Reda et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension J Am Coll Cardiol 59 2012 901 909
40. M.C. Brandt, S. Reda, F. Mahfoud, M. Lenski, M. Bohm, and U.C. Hoppe Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension J Am Coll Cardiol 60 2012 1956 1965
41. N.B. Shulman, C.E. Ford, and W.D. Hall et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group Hypertension 13 1989 I80 I93
42. M.J. Klag, P.K. Whelton, and B.L. Randall et al. Blood pressure and end-stage renal disease in men N Engl J Med 334 1996 13 18
43. S.G. Rostand, J.D. Brunzell, R.O. Cannon III, and R.G. Victor Cardiovascular complications in renal failure J Am Soc Nephrol 2 1991 1053 1062
44. P. Hamar, G. Kokeny, and P. Liptak et al. The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model Nephron Exp Nephrol 105 2007 e124 e136
45. K. Rafiq, T. Noma, and Y. Fujisawa et al. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation Circulation 125 2012 1402 1413
46. D.A. Calhoun, D. Jones, and S. Textor et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation 117 2008 e510 e526
47. S.L. Daugherty, J.D. Powers, and D.J. Magid et al. Incidence and prognosis of resistant hypertension in hypertensive patients Circulation 125 2012 1635 1642
48. U. Zeymer, R.E. Schmieder, and T. Riemer et al. Incidence of resistant hypertension and prognostic impact on clinical events during 2-year follow-up in outpatients with hypertension. Results of the 3-A registry J Hypertens 31 e-Suppl. A 2013 [Abstract 4A.05]
49. R.T. Gansevoort, J.C. Verhave, and H.L. Hillege et al. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population Kidney Int Suppl 2005 S28 S35
50. E.C. Witte, H.J. Lambers Heerspink, D. de Zeeuw, S.J. Bakker, P.E. de Jong, and R. Gansevoort First morning voids are more reliable than spot urine samples to assess microalbuminuria J Am Soc Nephrol 20 2009 436 443
51. J.P. Howard, A.N. Nowbar, and D.P. Francis Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4121 patients with focus on trial design: the CONVERGE report Heart 99 2013 1579 1587